清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

肺炎球菌疫苗 肺炎链球菌 免疫学 血清型 流感疫苗 肺炎球菌感染 免疫 病毒学
作者
Lisa A. Jackson,Alejandra Gurtman,Kathryn Rice,Karlis Pauksens,Richard N. Greenberg,Thomas R. Jones,Daniel A. Scott,Emilio A. Emini,William C. Gruber,Beate Schmöele-Thoma
出处
期刊:Vaccine [Elsevier]
卷期号:31 (35): 3585-3593 被引量:158
标识
DOI:10.1016/j.vaccine.2013.05.010
摘要

The currently recommended single dose of the 23-valent pneumococcal free polysaccharide vaccine (PPSV23) for adults 65 years of age and older does not provide extended protection into older age. This reflects a significant unmet medical need for alternative strategies to protect older adults against pneumococcal infection, which may be met by the 13-valent polysaccharide conjugate vaccine (PCV13). We performed a randomized, modified double-blind trial in 936 adults aged 70 years and older who had previously received PPSV23 at least 5 years before study entry and were now vaccinated with PCV13 or PPSV23. At 1 year after enrollment, all subjects received a follow-on dose of PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured before and at 1 month after each vaccination. Following the enrollment vaccination, OPA titers were significantly greater in the PCV13 group compared to the PPSV23 group for 10 of the 12 serotypes common to both vaccines and to serotype 6A which is unique to PCV13. Responses were noninferior for the other 2 common serotypes. Responses to PCV13 given at 1 year were generally lower in the group that received PPSV23 at enrollment. In adults aged 70 years and older previously vaccinated with PPSV23, PCV13 was significantly more immunogenic than PPSV23 for most of the common serotypes and for serotype 6A. The OPA responses after a follow-on dose of PCV13 one year later indicate that a prior dose of PPSV23, but not PCV13, diminishes the response to the subsequent administration of PCV13.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
苗笑卉完成签到,获得积分10
6秒前
万灵竹完成签到 ,获得积分10
8秒前
Regina完成签到 ,获得积分10
8秒前
今后应助一个小胖子采纳,获得10
15秒前
飞快的冰淇淋完成签到 ,获得积分10
27秒前
小蘑菇应助科研通管家采纳,获得10
29秒前
orixero应助一个小胖子采纳,获得10
33秒前
热心采枫完成签到 ,获得积分10
35秒前
janer完成签到 ,获得积分10
49秒前
50秒前
宇文雨文完成签到 ,获得积分10
54秒前
54秒前
共享精神应助一个小胖子采纳,获得10
1分钟前
小西完成签到 ,获得积分10
1分钟前
幸福书琴完成签到 ,获得积分10
1分钟前
SciGPT应助一个小胖子采纳,获得10
1分钟前
Phoenix ZHANG完成签到 ,获得积分10
1分钟前
充电宝应助一个小胖子采纳,获得10
1分钟前
丘比特应助一个小胖子采纳,获得10
1分钟前
lifeup完成签到 ,获得积分10
2分钟前
2分钟前
taster发布了新的文献求助10
2分钟前
今后应助一个小胖子采纳,获得10
2分钟前
Owen应助taster采纳,获得10
2分钟前
2分钟前
kk驳回了大模型应助
2分钟前
慕青应助科研通管家采纳,获得10
2分钟前
2分钟前
hff应助一个小胖子采纳,获得10
2分钟前
cyskdsn完成签到 ,获得积分10
2分钟前
终究是残念完成签到,获得积分10
2分钟前
kenchilie完成签到 ,获得积分10
2分钟前
凉面完成签到 ,获得积分10
2分钟前
hff应助一个小胖子采纳,获得10
2分钟前
蚂蚁踢大象完成签到 ,获得积分10
2分钟前
jensen应助一个小胖子采纳,获得10
3分钟前
Singularity举报小鲸鱼求助涉嫌违规
3分钟前
居居侠完成签到 ,获得积分10
3分钟前
一个小胖子完成签到,获得积分10
3分钟前
倪小呆完成签到 ,获得积分10
3分钟前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Ethnicities: Media, Health, and Coping 700
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3088549
求助须知:如何正确求助?哪些是违规求助? 2740715
关于积分的说明 7561203
捐赠科研通 2390734
什么是DOI,文献DOI怎么找? 1267982
科研通“疑难数据库(出版商)”最低求助积分说明 613947
版权声明 598678